
Confero Healthcare Private Limited
Founded in 2011 and headquartered in Telangana, India.
Founded in 2011 and headquartered in Telangana, India.
Hyderabad, Telangana, India
+91-XXXXXXXXXX
-
U24232TG2011PTC075131
075131
Private Limited Indian Non-Government Company
22 Jun 2011
-
-
Unlisted
Roc Hyderabad
Name | Designation | Appointment Date | Status |
---|---|---|---|
Gayathri Malleboina ![]() | Director | 24-May-2017 | Current |
Laxman Donkani ![]() | Director | 24-May-2017 | Current |
Confero Healthcare Private Limited, for the financial year ended 2017, experienced significant growth in revenue, with a 24.45% increase. The company also saw a substantial improvement in profitability, with a 38.87% increase in profit. The company's net worth Soared by an impressive increase of 17.47%.
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
In 2017, Confero Healthcare had a public holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
There are no open charges registered against the company as per our records.
Unlock and access historical data on people associated with Confero Healthcare, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Confero Healthcare, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Confero Healthcare's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Gayathri Malleboina was appointed as a Director was appointed as a Director on 24 May 2017 & has been associated with this company since 7 years 9 months .
24 May 2017
Laxman Donkani was appointed as a Director was appointed as a Director on 24 May 2017 & has been associated with this company since 7 years 9 months .
24 May 2017
Confero Healthcare Private Limited was registered on 22 Jun 2011 with Roc Hyderabad & aged 13 years 8 months as per MCA records.
22 Jun 2011
Confero Healthcare Private Limited was incorporated on 22 Jun 2011.
The authorized share capital of Confero Healthcare Private Limited is ₹ 1.00 M and paid-up capital is ₹ 0.10 M.
Currently 2 directors are associated with Confero Healthcare Private Limited.
As per Ministry of Corporate Affairs (Mca), the registered address of Confero Healthcare Private Limited is Flat No.103 H.No. 1-2-10/4 Evr Shardha Street No.2, Habsiguda India, Hyderabad, Telangana, 500007.
The corporate identification number (CIN) of Confero Healthcare Private Limited is U24232TG2011PTC075131 and the company number is 075131 as per Ministry of Corporate Affairs (MCA).
According to the financial reports for the fiscal year 2017, the revenue trend for Confero Healthcare Private Limited has risen by 24.45%.
The financial reports for the fiscal year 2017 indicates that The net worth of Confero Healthcare Private Limited has experienced an upsurge of 17.47%.